Based on the findings, updated from results published in January in Cancer, Spectrum expanded the development program for Zevalin to include support for a larger, randomized international study using the Z-BEAM regimen as a preparative regimen for patients with lymphoma who receive autologous stem cell transplantation
At the 17th Congress of the European Hematology Association in Amsterdam, Max Topp, of the University of Wuerzberg, Germany presented the results of a Phase II study evaluating the efficacy, safety and tolerability of bispecific antibody blinatumomab (Micromet Inc.) in adult patients with B-precursor acute lymphoblastic leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant
Seattle Genetics Inc., of Bothell, Wash., reported updated survival data from a pivotal trial of single-agent Adcetris (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant, showing that the median overall survival has not been reached after a 26.5-month median follow-up
Those data showed that ICT down-regulates tumor-associated antigens as well as cancer stem cell marker CD-133, in some patients...The results supported the strategy of targeting antigens that are highly expressed by cancer stem cells
The trial, which is evaluating the safety and preliminary efficacy of the company's HuCNS-SC cells (purified human neural stem cells), represents the first time neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury
Cytomedix Inc., of Gaithersburg, Md., said the independent data safety monitoring board recommended that the Phase II trial of ALD-401, a differentiated stem cell population derived from patients' own bone marrow, can continue as designed, following a review of the safety data on the first 10 patients treated post-acutely for ischemic stroke
JVS-100 is designed to encode stromal cell-derived factor 1, which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow
Celgene International Sarl, a subsidiary of Celgene Corp., of Summit, N.J., said three Phase III trials of Revlimid (lenalidomide) in multiple myeloma supported the growing body of evidence for use of the drug in newly diagnosed patients and in maintenance treatment following autologous stem cell transplant
Neuralstem Inc., of Rockville, Md., said the FDA approved the return of three patients from earlier cohorts in its ongoing Phase I trial testing its spinal cord stem cells (HSSCs) in amyotrophic lateral sclerosis...They will be the first to receive stem cell transplantation along the length of the spinal cord
Magellan MAR01 is designed to enable the rapid operating room-based "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells in as little as 15 minutes
said final results from a Phase IIb (RESTORE-CLI) trial of ixmyelocel-T, a stem cell therapy for critical limb ischemia, showed improved time to treatment failure (62 percent risk reduction) compared to the control group
StemCells Inc., of Newark, Calif., reported preliminary evidence of progressive and durable donor cell-derived myelination in all four patients who underwent transplantation with the company's HuCNS-SC cells (purified human neural stem cells) in its Phase I trial in Pelizaeus-Merzbacher disease, a rare hypo-myelination disorder in children
The findings, reported online in Stem Cells, indicated one patient showed improved clinical status, although the study was not designed to show efficacy...None of the patients, who were followed for six to 18 months after they received stem cell transplants in the lumbar region, showed evidence of accelerated disease progression due to the intervention
Seattle Genetics Inc., of Bothell, Wash., said results of its pivotal trial of antibody-drug conjugate Adcetris (brentuximab vedotin) published in the Journal of Clinical Oncology demonstrated that treatment with the drug as a single agent induced durable objective responses in 75 percent of Hodgkin lymphoma patients who have relapsed or refractory disease following an autologous stem cell transplant
SanBio Inc., of Mountain View, Calif., said it completed enrollment in the first dose cohort in its Phase I/IIa study testing allogeneic stem cell therapy product SB623 in patients with chronic deficits resulting from previous stroke injuries
ALD-201, developed by Aldagen Inc., of Durham, N.C., is a population of biologically instructive adult stem cells (aldehyde dehydrogenase bright cells, or ALDH[br]) selected from a patient's own bone marrow using the ALDH enzyme as a marker...Findings also could be used to calculate effective doses for Phase II trials of I-131-CLR1404 (HOT), the company's chemically identical small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic, which is designed to deliver cytotoxic radiation
Baxter International Inc., of Deerfield, Ill., said it started a pivotal Phase III study testing adult autologous CD34-positive stem cells to increase exercise capacity in patients with chronic myocardial ischemia...The primary objective is to evaluate the efficacy of the stem cells by measuring the change in total exercise capacity at 12 months following treatment
Gentium SpA, of Villa Guardia, Italy, said a Phase III trial evaluating defibrotide in preventing hepatic veno-occlusive disease (VOD) in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) showed that use of defibrotide led to a 40 percent reduction in the incidence of VOD 30 days after HSCT
Based on the findings, updated from results published in January in Cancer, Spectrum expanded the development program for Zevalin to include support for a larger, randomized international study using the Z-BEAM regimen as a preparative regimen for patients with lymphoma who receive autologous stem cell transplantation